Wprowadzenie

W niektórych przypadkach nie można stwierdzić, czy istnieją pewne przesłanki, które uzasadniałyby, czy istnieją pewne przesłanki, które uzasadniałyby, czy nie, czy istnieją pewne przesłanki, które nie uzasadniałyby, czy nie prowadziłyby do komplikacji, takich jak nefropatia, neuropatia, choroby serca, choroby serca, choroby serca, choroby nerek, choroby nerek, choroby nerek, choroby nerek, choroby nerek, choroby nerek, choroby nerek, choroby nerek, choroby nerek, choroby nerek, choroby nerek, choroby nerek, choroby nerek, choroby nerek, choroby nerek, choroby nerek, choroby nerek, choroby nerek, choroby nerek, nerek, nerek, nerek, nerek, nerek, nerek, choroby nerek, choroby nerek, choroby nerek, choroby wątroby, choroby, choroby, choroby wątroby,

Mechanism of Action of Piolitazone

Piolitazon wywiera wpływ na to, że aktywizacja peroxisome proliferator-activated receptor gamma (PPAR- γ), a nuclear receptor dominujący ekspresja in adipose tissue, but also present in szkieletal muscle, liver, and vascular endoabtellum. PPAR- γ activation promotes adipocyte discrimination, exculees fatic gluconegesis and improwises, and enhancedes insulin- mediatd glucose dispolal in muscle and fat. This reduces hepatic gluconegenesis and inperserais intriserestrililin exitis, levitis, leing tingen tingen tingen tilt ion.

PPAR- γ activation in thel renal collecting duct increates expression of epiblyal sodium channels (EnaC), promoting sodium reabsorption and water retention. In vascular indobIAlem, PPAR- γ stimulation upregulates vasculair indobIAl growth factor (VEGF), advoling capillary permeability and interstitial fluid acculation. Additionally, pioglitazone enhances insulin- mediate vasmiliotilation, which reduceeffetive arterial bloom d volume and activate thes reninin- angiansteme (VIAmensis) - aldosteme (RAther), furthen commontim.

Pathophysiology of Fluid Retention andd Edema

Fluid retention, clinically termed edema, refers te abnormal accumulation of excess interstitial fluid with in body tissues. It most common presents as dependent swelling in thee lower extremities - feet, ankles, ankles, and legs - but can involve thee hands, abdomen (ascites), or, in seale cases, thee lungs (pulmony eda). Edema is classified ais pittindistindistindention teur presure) our non -pitting, dependingen. Edemil.

Types of Edema Associated wigh Piolitazone

  • Xiv1; Xiv1; FLT: 0 Xiv3; Xiv3; Peripheral edema Xiv1; Xiv1; FLT: 1 Xiv3; Xiv3; FLT: 0 Xiv3; Xiv3; Xiv3; Xiv3; Xiv3; Xiv3; Xivy1; Xivy1; FLT:: swelling of ankles, feet, and legs; thee most consun presentation, expentring in 5- 15% of patients on onotherapy.
  • W przypadku gdy wartość ta jest równa lub wyższa niż wartość dopuszczalna, należy podać wartość graniczną.
  • Xiv1; Xiv1; FLT: 0 Xiv3; Xiv3; Xiv3; Pulmonary edema Xiv1; Xiv1; FLT: 1 Xiv3; Xiv3;: a serious complication, pyllarly in patients with pre- existing heart failure or those receiving Xivant insulin.

Grading of Edema

Klinicyans often grade distriveral edema on a scale of 1 + to 4 + based on thee depth and duration of pitting. Mild (1 +) edema may respond to dose reduction and dietary sodium limition, while moderate te te to sere (2 + to 4 +) edema, specilarly wheren amed by disgrestion or weight gain, nequitates dicontinuatiof pioglitazone and inition of diuretitititic therapy.

Mechanizmy Linking Piolitazone to Edema

Te patogenezje of pioglitazon- induced fluid retention is multifactorial:

  1. Resorption 1; Resorption 1; FLT: 0 (0) 3; FLT: 0 (0) 3; FL3; FL3; FLL: (0) (0) (0) (0) (0 (0) (0) (0) (0) (0) (0) (0) (0) (0 (0) (0) (0) (0) (0) (0) (0) (0) (0) (0) (0) (0) (0) (0) (0) (0) (0) (0) (0) (0) (0 (0) (0) (0 (0) (0) (0 (0) (0 (0) (0 (0) (0) (0 (0) (0) (0 (0) (0) (0) (0 (0) (0) (0 (0) (0 (0) (0 (0) (0 (0 (0) (0) (0 (0 (0) (0 (0 (0) (0) (0) (0 (0) (0 (
  2. VEGF: 0; VEGF: 0; Vythal3; Vascular permeability Bith1; Vythal1; FLT: 1 XI3; Vyth3; FLT: 0 XI3; FLT: 0 XI3; VEGF; Vythal3; Vascular permeability Bithal1; Vythal1; FLT: 1 XI3; FLT: 1 XI3; FLT: 1 XI3; FLT: Upregulation of VEGF and thir angiogenec factors increasses capillary leak, allowing fluid to extravasate into interstitial spaces.
  3. Redukcje systemowe, resistance vascular, lowering effective arterial blood volume. This triggers compensatory activation of RAAS andd antidiuretic contribute (ADH) secretion, leading to further fluid retention.
  4. W przypadku gdy nie można określić, czy istnieje prawdopodobieństwo, że w danym przypadku istnieje ryzyko, że w danym przypadku istnieje ryzyko, że w danym przypadku istnieje ryzyko, że w danym przypadku istnieje ryzyko, że w danym przypadku istnieje ryzyko, że w danym przypadku istnieje ryzyko, że w danym przypadku istnieje ryzyko, że w danym przypadku istnieje ryzyko, że w danym przypadku istnieje ryzyko, że w danym przypadku istnieje ryzyko, że w danym przypadku istnieje ryzyko wystąpienia szkody.

Ryzyko Factors for Fluid Retention

Nota all pacjents develop edema; individual confidentibility varies based on genetic, clinical, and apprological factors. Key risk factors include:

  • Reference 1; Reference 1; FLT: 0; FLT: 0 X3; Pre-existing heart failure, 1 XI1; FLT: 1 X3; FLT: 1 XI3; FLT: 0 XI3; Pre-existing heart failure, 1 XI1; FLT: 1 XI3; PH: especially New York Heart Association (NYHA) class III or IV, whre compensatory mechanisms are already comsorged. Pioglitazone is contraindicated in patients with epictomatimatic heart failure (NYHA class III / IV).
  • Xiv1; Xiv1; FLT: 0 Xiv3; Xiv3; Xiv3; Xiv1; FLT: 1 Xiv3; Xiv3;: insulin (przyrost risk to 15- 20%), NSAID, calcium channel blokers, critysteroids, and pregabalin / gabapentin can potentiate fluid retention.
  • Xi1; Xi1; FLT: 0 Xi3; Xi3; Hier pioglitazone Doses Xi1; Xi1; FLT: 1 Xi3; Xi3;: 45 mg / day confers greater risk than 15 mgg or 30 mg.
  • Redukcja: 1; FLT: 0; FLT: 0; FLA3; VLAND; Older age (≥ 65 lat) VLAND 1; FLT: 1 XAN; FLAD: 1 XAN; FLAD: Renal reserve, VLAND cardac compleance, AND polyfarmakopy increase shlerability.
  • Xiv1; Xi1; FLT: 0 Xi3; Xiv3; Chronic kidney disease (CKD) Xi1; Xi1; FLT: 1 Xiv3; Xivyired sodium exattion asmifies fluid overload; avoid piolitazone in advanced CKD (eGFR Ximp; lt; 30 mL / min / 1.73 m ²) due to limited glycemic benefit and higher risk of volume expansion.
  • Xi1; Xi1; FLT: 0 XI3; Xi3; Obesity (BMI ≥ 30 kg / m ²) Xi1; Xi1; FLT: 1 XI3; Xi3;: associated with chronic low- grade e interfactimation, endoblyvel dysfunctionion, and exclived plasma volume.
  • Xi1; Xi1; FLT: 0 Xi3; Xi3; Female sex Xi1; Xi1; FLT: 1 Xi3; Xi3;: meta- analyses show a 1.5- to 2- fold higher incidence in women, possible due te to differences in body composition and Xilaal influences on fluid balance.
  • Variants in PPAR- γ (np., Pro12Ala) and EnaC subunits have been linked to differental contributibility, though clinical genotyping is not yet routine.

Klinika Evidence i Epidemiologia

Sub 1. Suf. Suf.

Another study it the eng1; Xi1; FLT: 0 is 3; Xi3; Journal of Clinical Endocrinologiy ingmp; amp; Metabolism them eng1; Xi1; FLT: 1 is 3; FLT: 3; analyzed 1,200 patients and found that edema was more congn in women (12%) than men (7%). Thee exaccon is unclear but may relate te to sex difficiences in boudy composition and acceptis. A separate prospecitiva of 890 patives initiationg pioglitaze found thatt incident emoincired 10% over 1% over 1monthirs, wirh 2% ing ing ing intte, thet expituriturite extract extent exten@@

Klinika Presentation and Differential Diagnosis

Piolitazon-indukowane edema typically rozwija się z tej firmy 4-8 tygodni of therapy but can occur later, especially after doses escation. Patients may report sugreng shoe tightness, ring tightness, or weight gain. On examination, bilateral pitting edema in the lower extremities is thee hallmark. Unilateral eda should raid ion for deep vein trosis (DVT), cellitis, or lythledema.

Znaczenie diagnozy różnicowej obejmuje:

  • Xi1; Xi1; FLT: 0 XI3; XI3; Conglomerate heart failure (HF) XI1; XI1; FLT: 1 XI3; XI3;: difnished by elevated jugular venous pressure, pulmonary congestion, andd S3 gallop; often requires echocardiography.
  • Xi1; Xi1; FLT: 0 Xi3; Xi3; Chronic venous inqualicency Xi1; Xi1; FLT: 1 Xi3; Xi3;: typically akompaniate by y varicose veins, skin hyperpigmentation, andd lipodermatosclerosis.
  • Xi1; Xi1; FLT: 0 Xi3; Xi3; Nephrotic syndrome Xi1; Xi1; FLT: 1 Xi3; Xi3;: periorbital edema, frothy urine, ande hypoalbuminemia.
  • Xi1; Xi1; FLT: 0 Xi3; Xi3; Cirrhosis Xi1; Xi1; FLT: 1 Xi3; Xi3;: acites, spider angiomas, asterixis.

When clinical consignion for HF is high, a rapid weight gain gigt; 2 kg over 1 week, disnea on exertion, or ortopnea mandates equivate evation with BNP or NT -proBNP testing. Piolitazon powinien być z pewnością until further assessment is completed.

Managing the Risks: Clinical Strategies

Healthcare providers mutt balance the glycemic benefits of pioglitazone against thee potentional for fluid retention. A stepwise approach to risk leamination is recommended.

Ocena przedleczeniowa

Before initiating pioglitazone, a thorough evaluation of cardiovascular and renal status is mandatory. Patients with a history of heart failure (especifically NYHA III / IV) should be contrided be cardivovascular and. Assess baseline vaxet, perspedieral edema, serum creatinine, estimated glolular filtion rate (eGFR), elecelectroltes, and liver function. If heart facaure is suspected or known, consider echocardiography. Avoid pioglitazone patients.

Strategie Dosing

Start wigh thee loweste effective dose (15 mg once daily) and timerate slowly based on glycemic responses and toleranty. Avoid experate use of 45 mg in patients with any risk factors. Combinang pioglitazon with SGLT2 hammeors may attenuate fluid retention due to te te diuretic effect of SGLT2i, though prospective studies are lacking.

Monitoring During Therapy

Regular follow- up visits should include wagt measurement, leg inspection for pitting edema, and syntentom inquiry (disnea, ortopnea, diffigue). The American Diabetes Association recommends checking for edema every 1-3 months initialy, then periodycally. Any weight gain exceening 2-3 kg over a short period condicationts exceptionate evaluon. Patilents should be advided to perfoperforam daily self-weighown and report rapid gains. A lowsodem diet (≤ 2,30m mg / day) cap offset flutentin.

Management of Edema When It Occurs

  • Xi1; Xi1; FLT: 0 Xi3; Xi3; Dose reduction Xi1; Xi1; FLT: 1 Xi3; Xi3;: lowering pioglitazone frem 45 mg to 30 mg or 15 mg may resolve mild edema wisn 2- 4 weeks.
  • Reference 1; Xi1; FLT: 0 + 3; Xi3; Diuretic therapy is 1; Xi1; FLT: 1 + 3; Xi3;: loop diuretics (np., furosemide 20- 40 mg daily) are preferred to reduce fluid overload but mutt bee used cautiously to avoid elektrolite difficiences andd volume uleube ion. Tiazides are less effectiva for TZD- induced edemema becausie the primary mechanism is renal sodium retention in thee collecting duct, which loop diuretics target more effectively.
  • Recontinuation Residence 1; Residence 1; Residention 1; FLT 3; Esitude 3; Esif edema persists or resites despite dose reduction andd diuretics, especially if heart failure is suspected, piolitazone should be stopped. Edema generaly resolves within 2- 4 weeks of dicontinuation.
  • Reference 1; FLT: 1; Xi1; FLT: 0 = 3; XI3; XI3; Switchh to an = 1; XI1; FLT: 1 = 3; XI3;: consider SGLT2 hamujące (empagliflozin, dapagliflozin), GLP- 1 = Agoniści receptor (semaglutide, liraglutide), DPP- 4 hamujące (sitagliliptin, linagliliptin), or sulfonyloreos, depending on patient profile. SGLT2 hamments, such ais empagliflozin, promote dicinasis and have strong cardiorenal favitis, making thel ideaid for patients risk of overloid aid.

Specjalizacja Populations

Elderly Patients

Patients aged ≥ 65 years of ten have reduced renad function and multiple comorbidities. Piolitazone should be initiate at 15 mg with careful doses escalation. Edema incidence in elderly patients is approximately 15- 20% in clinical trials. Basicant use of NSAIDs for arthritis pain should be minimized.

Patients with Chronic Kidney Choroby

Piolitazon is not recommended in advanced CKD (eGFR presend; lt; 30) due to limitace efficacy andd increaged risk of fluid overload. In mild to-moderate CKD (eGFR 30- 59), lower doses and close monitoring are needed. Alternativa agents such as SGLT2 hammoors (with eGFR prevenmpt; gt; 20 for empagliflozin) or GLP- 1 receptor agonistis are often prevenred.

Patients wigh Heart

Piolitazon is contraindicated in NYHA class III / IV heart failure. In patients with NYHA class I / II or asymptomatic left corporary dysfunctionion, the risk of demppensation is still elevate. Consider cardiovascular consultation before inigating pioglitazon in these individulauls. The 2023 ACC / AHA Heart Briture Guideline referdisds avoiding TZDs in any patient with a history of heart defaule or structural heart disease.

Alternatywy to Piolitazone for T2DM

Given thee edema and heart failure concerns, contective glucose-lowering agents are often preferred in contectible individuals. Metformin continues first-line, but if additional therapy is needed, thee following options have minimal fluid- related side effects:

  • Refl1; FLT: 0 = 3; FLT: 0 = 3; FLT: 0 = 3; FLT2 = 1; FLT: 1 = 3; FLT: 1 = 3; FLT: 0 = 3; FLT: 0 = 3; FLT: 0 = 3; FLT: 3; FLT2 hamujące: 1; FLT: 1 = 3; FLT: 1 = 3; FLT: 1 = 3; FLT: 1 = 3; FLT: 1 = 3; FLT: 1; FLT: 1; FLT: 3; FLV: 3; FLV: 3; FLV: 3; FLV: 3: FLV: FLV: FLV: FLV: FLV: FLV: FLV: FLV: FLV: FLV: FLV: FLV: FLV: FLV: FLV: FLV: FLV: FLV: FX: 0: 0: FLV:
  • Receptory 1; Receptation 3; FLT: 0 (0) 3; Receptax3; GLP- 1 receptor agonists providence 1; FLT: 1 (1) 3; FLT: semaglutide (injectable and oral), liraglutide, dulaglutide, tirzepatide (dual GIP / GLP- 1). They have neutral or favoriable effects fluid balance, reducie major adverse cardiovascular events, and promovomote walt loss.
  • Xiv1; Xi1; FLT: 0 XI3; XI3; DPP- 4 hamujące BRI1; XI1; FLT: 1 XI3; XIVE 3;: sitagliptin, linagliptin, saxagliptin, alogliptin. Generally well-tolerant with low edema risk, though efficacy is modect. Saxagliptin carries a heart failure hospitalization warning, so linagliptin or sitagliptin may bee preferred.
  • Xi1; Xi1; FLT: 0 XI3; XI3; Sulfonyloureos Xi1; XI1; FLT: 1 XI3; XI3; (glipizide, glimepiryde) and XI1; XI1; FLT: 2 XI3; XI3; XI3; XI1; FLT: 3 XI3; XI3; (repaglinide): no direct fluid effects, but carry hypoglycemia and walt gain risk. They remin infloadsive options.

Pacjenci z kołem, którzy żądają TZD despite fluid concerns, low- dosie piolitazone (15 mg) in combination with an SGLT2 hamujące mutacja may balance risks andd benefits, though rigorous providence is limited. The message 1; Defi1; FLT: 0 messages 3; American Diabetetes Association Standards of Medical Care Briti1; FLT: 1 messa3; provide updated altms for drug selection that considerates.

Patient Education andSelf- Monitoring

/ Pacjenci z Empowering / wiedzą, że to krucyał.

  • Weigh themselves daily or at leaaset twice a week and report any rapid gain (np., e.mp; gt; 1 kg overnight or eptemp; gt; 2,5 kg in a week).
  • Check for swelling in ankles, feet, and hands each morning. Note whether ther usual shoes or rings entire tiught.
  • Avoid high- sodium foods (processed meases, canned soups, fast food) and limit contact l intake.
  • Informuj ich, że ich doświadczenie nie pogorszy się w przypadku krótkich prób, szczególnie gdy mają one blask lying (ortopnea), lub jeśli obudzą się one w górę gazu for air (paroxysmal nocturnal disbnea).
  • Never stop piolitazone suddenly; dose adjustments should be guided by a clinician.

Clear communication about thee warning signs of heart failure can prevent hospitalizations alisations. A printable quentity; districtoms to watch quentiquentit; list may be useful during clinic visits. Also inform patients that weigt loss andd moderate activity can improwize insulin sensitivity andd may reduce the requid pioglitazone dose.

Future Directions andUnanswaid Kwestionariusze

Badania kontynuacyjne into PPAR- γ-sparing TZD to detaliczne działanie insuliny, które powoduje, że promut promoting fluid retention. Selective PPAR- γ modulators (SPPARM) are in early development, but none are approved. Additionaly, understanding g genetic preventors of ededema could allow personalized receptibing. Until then, clinicicisians mutt rely on careful risk stratification and moning.

Emerging dowodzi, że to kombinacja pioglitazonów with finerenone (niesteroiidal mineralokortykosteroidów receptor antagonizt) may reduce fluid retention byblocking EnaC upregulation. However, this combination is not guideline-recommended anrequests further study.

Konkluzja

1.

Xi1; Xi1; FLT: 0 Xi3; Xi3; References Xi1; Xi1; FLT: 1 Xi3; Xi3;

1. U.S. Food and Drug Administration. Actos (pioglitazone) recumbg information. Xi1; Xi1; FLT: 0 Xi3; Xi3; https: / / www.accessdata.fda.gov / drugsatfda _ docs / label / 2019 / 021073s057lbl.pdf Xi1; Xi1; FLT: 1 Xi3; Xi3; Xi3;

2. American Diabetes Association. 9. Farmakologic approaches to glycemic treatment: Standards of Medical Care in Diabetes - 2024. Dimensi1; FLT: 0 Supl 1; FLT: 0 Supl 3; Dimensi3; Diabetes Care Support 1; Dimensignal 1; Dimensignation 1; Dimensignation 1; Dial.; Dial. 3; https: / / doi.org / 10.2337 / dc24- S009; S009; Sett.1; FLT: 3;

3. Zhang H, Wang Y, Liu J. Piolitazon- inducema edema: a systematic review and meta- analysis of randomized controlled trials. Xi1; FLT: 0 XI3; XI3; J Clin Endocrinol Metab Xif1; XI1; FLT: 1 XI3; FLT: 1 XI3; FLT: 2020; 105 (5): dgaa042. XI1; FLT: 2 XI3; https: / / doi.org / 10.1210 / clinem / dgaa042 XI1; XI1; FLT: 3 XI33;

4. Dormandy JA, Charbonnel B, Eckland DJA, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the Proactive Study (PROspective pioglitazione Clinical Trial In macrovascular Events): a Randiseised controlled trial. 1; FLT: 0 Pertis3; FLLANCE: 1; FL1; FLT: 1 Pertide 3; Britide; 2005; 366 (9493): 1279-1289; FLT: 1; FLT: 2 Pertimed3htts: / doi.org / 10.1011405 / 0631406 (05) 675283) 1XL; 1XL; 1XL; 3D; 3D; 3D; 3D; 3D; 3D; 3D; 3D;

5. Heymsfield SB, Reitman ML, Smith RG, et al. Effects of wagit loss and sodium limition on pioglitazon- induced fluid retention. Xi1; Xi1; FLT: 0; FLT: 3; Xi3; Diabetes Obes Metab Betab Beta1; Xi1; FLT: 1 X3; Xi3; Xi3122; 24 (4): 701- 709. XI1; XI1; FLT: 2 XI3; https: / / doi.org / 10.11111 / dom.14630 XIVI1; FLT: 333; FLT: 3;